Rallybio sets 1-for-2 reverse stock split effective Nov. 20 ahead of Avenzo merger

Rallybio Corp

Board approved a one-for-two reverse split on Nov. 8, 2026; effective 12:01 a.m. ET on Nov. 20, 2026, before the anticipated merger close.
Issued and outstanding shares will fall from about 5.6 million to about 2.8 million; authorized shares and $0.0001 par value remain unchanged.
After Nasdaq approvals and merger close, Rallybio plans to rename itself Avenzo Therapeutics and trade under ticker "AVZO" with CUSIP 053928 107.
Merger agreement dated May 31, 2026 with Avenzo Therapeutics and Farmington Merger Sub; stockholders approved a split range of 1-for-2 to 1-for-9 on Nov. 4.
No fractional shares will be issued; holders will receive cash equal to fair market value based on the closing price on the split's effective date, with Computershare as exchange agent.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.